News Gilead Sciences, Inc. Sao Paulo

Equities

Market Closed - Sao Paulo Other stock markets 11:21:12 10/05/2024 pm IST			5-day change	1st Jan Change
169.9 ^BRL	-1.92%		+3.77%	-11.73%

09/05	Declaration of Voting Results by Gilead Sciences	CI
09/05	Declaration of Voting Results by Gilead Sciences	CI

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program	10/05	BU
Declaration of Voting Results by Gilead Sciences	10/05	CI
Declaration of Voting Results by Gilead Sciences	10/05	CI
Declaration of Voting Results by Gilead Sciences	10/05	CI
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program	10/05	CI
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	07/05	MT
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024	07/05	BU
UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating	02/05	MT
Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75	01/05	MT
Maxim Adjusts Price Target on Gilead Sciences to $85 From $90	01/05	MT
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $117 From $120	01/05	MT
Gilead Sciences to Present at Upcoming Investor Conferences	01/05	BU
Barclays Adjusts Price Target on Gilead Sciences to $76 From $80	29/04	MT
TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90	26/04	MT
Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95	26/04	MT
RBC Capital Adjusts Gilead Sciences' Price Target to $74 From $76	26/04	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80	26/04	MT
Gilead Sciences Receives FDA Approval for Updated Label of Biktarvy	26/04	MT
Well, it isn't as bad as feared...	26/04
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV	26/04	BU

No results for this search